Amgen (AMGN) Tops Q2 EPS by 51c; raises guidance
Tweet
Share
E-mail_58cbc46cd3c33.jpg)
Get Alerts AMGN Hot Sheet
Price: $437.23 -1.55%
EPS Growth %: +2.7%
Financial Fact:
Interest and other income, net: 216M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +2.7%
Financial Fact:
Interest and other income, net: 216M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported Q2 EPS of $5.00, $0.51 better than the analyst estimate of $4.49. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.67 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $17.80-$18.80, versus the consensus of $17.75. Amgen sees FY2023 revenue of $26.6-27.4 billion, versus the consensus of $26.56 billion.
For earnings history and earnings-related data on Amgen (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Planet Labs (PL) Tops Q2 EPS by 4c, Offers Guidance
- Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
